|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2100046379 |
|
最近更新日期: Date of Last Refreshed on: |
2021-12-21 02:31:27 |
|
注册时间: Date of Registration: |
2021-05-15 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
请于伦理委员会批准后才开始征募参试者,并与我们联系上传伦理批件。 关于无精症患者显微取精结局的circRNA预测模型的前瞻性研究 |
|
Public title: |
A prospective study of circRNA prediction model for outcome of microsurgical sperm retrieval in azoospermia patients |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
精浆circRNA用于预测特发性非梗阻性无精子症患者显微取精结局的研究 |
|
Scientific title: |
Seminal plasma circRNA as a predictor of outcome of microejaculation in patients with idiopathic non obstructive azoospermia |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
张玺 |
研究负责人: |
宋宁宏 |
|
Applicant: |
Zhang Xi |
Study leader: |
Song Ninghong |
|
申请注册联系人电话: Applicant telephone: |
+86 18752132467 |
研究负责人电话:
Study leader's |
+86 13851490672 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
zhangxi199803@163.com |
研究负责人电子邮件: Study leader's E-mail: |
songninghong@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
江苏省南京市鼓楼区广州路300号 |
研究负责人通讯地址: |
江苏省南京市鼓楼区广州路300号 |
|
Applicant address: |
300 Guangzhou Road, Gulou District, Nanjing, Jiangsu |
Study leader's address: |
300 Guangzhou Road, Gulou District, Nanjing, Jiangsu |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
南京医科大学第一附属医院 |
||
|
Applicant's institution: |
The First Affiliated Hospital of Nanjing Medical University |
||
|
研究负责人所在单位: |
南京医科大学第一附属医院 |
||
|
Affiliation of the Leader: |
The First Affiliated Hospital of Nanjing Medical University |
||
|
是否获伦理委员会批准: |
否 |
||
|
Approved by ethic committee: |
No |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
伦理委员会批件附件: Approved file of Ethical Committee: |
||
|
批准本研究的伦理委员会名称: |
|
||
|
Name of the ethic committee: |
|
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2013-08-26 00:00:00 | ||
|
伦理委员会联系人: |
|
||
|
Contact Name of the ethic committee: |
|
||
|
伦理委员会联系地址: |
|
||
|
Contact Address of the ethic committee: |
|
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
南京医科大学第一附属医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The First Affiliated Hospital of Nanjing Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
江苏省南京市鼓楼区广州路300号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
300 Guangzhou Road, Gulou District, Nanjing, Jiangsu |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
南京医科大学第一附属医院 |
||||||||||||||||||||||
|
Source(s) of funding: |
The First Affiliated Hospital of Nanjing Medical University |
||||||||||||||||||||||
|
研究疾病: |
无精症 |
||||||||||||||||||||||
|
Target disease: |
Azoospermia |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
诊断试验 |
||||||||||||||||||||||
|
Study type: |
Diagnostic test |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
连续入组 |
||||||||||||||||||||||
|
Study design: |
Sequential |
||||||||||||||||||||||
|
研究目的: |
探究精浆中睾丸来源的circRNA在预测特发性非梗阻性无精子症患者显微取精结局方面的价值。 |
||||||||||||||||||||||
|
Objectives of Study: |
To explore the value of circRNAs derived from testis in seminal plasma in predicting the outcome of mTESE in patients with idiopathic non-obstructive azoospermia. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
特发性非梗阻性无精子症患者。 |
||||||||||||||||||||||
|
Inclusion criteria |
Idiopathic non-obstructive azoospermia patients. |
||||||||||||||||||||||
|
排除标准: |
无。 |
||||||||||||||||||||||
|
Exclusion criteria: |
No. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2021-05-10 00:00:00至 To 2023-05-10 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2021-05-10 00:00:00 至 To 2023-05-10 00:00:00 |
|
诊断试验: Diagnostic Tests: |
|
||||||||||||||||||||||||||||
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男性 |
Gender: |
Male |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
由张玺按简单随机方法进行分组,在整个研究中心按照受试者入选的先后顺序,根据预定的随机方案分配入试验组或对照组。随机方案通过计算机产生,随简单随机方法。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Zhang Xi will orgnize groups according to a simple random method, and in the entire research center, the subjects were assigned to the experimental group or the control group according to the predetermined randomization plan according to the order in which the subjects were selected. The random scheme is |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
试验结束后6个月内公开;在中国临床试验注册中心网站(www.chictr.org.cn)共享数据 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Open within 6 months after the end of the trial; share data on the website of China Clinical Trials Registry (www.chictr.org.cn) |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录由CRF表完成;数据采集和管理由ResMan完成 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Case records are completed by CRF tables and data acquisition and management by ResMan. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |